EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients

Emmanouil Panagiotou iD, Anastasia Georganta, Efstathios Garoflos, Eleftheria Karaviti iD, Dimitra Karaviti iD, Athanasios Kontogiannis iD, Sofia Chorianopoulou, Elias Kotteas iD, Nikolaos Syrigos, Melpomeni Peppa

Journal of Personalized Medicine · 02.03.2026 · 16 (3) · 140

DOI: 10.3390/jpm16030140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 02.03.2026. Verfasst von Emmanouil Panagiotou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11…. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Soluble receptor for advanced glycation end products (sRAGE) has emerged as a candidate biomarker in metabolic, inflammatory, and malignant diseases, although its prognostic significance in LC remains uncertain.

Methods

Serum sRAGE levels were prospectively measured at baseline and prior to the second cycle of treatment in patients with non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Associations of sRAGE with overall survival (OS), progression-free survival (PFS), clinical features, and other biomarkers were analyzed.

Results

In total, 42 patients were enrolled in this study. sRAGE was detected in 16 patients (38.1%) at baseline and in 15 patients (37.5%) after the first cycle of treatment. Pre-treatment sRAGE levels were strongly correlated with post-treatment levels (Pearson’s r = 0.78; 95% CI, 0.61–0.88; p = 4.1 × 10−9) and moderately correlated with PD-L1 tumor proportion score in NSCLC patients (Spearman’s ρ = 0.4, p = 0.049). Pre-treatment sRAGE levels tended to be higher in patients with indeterminate/high risk of liver fibrosis compared to patients with low risk (Wilcoxon rank-sum test, p = 0.041). Post-treatment change in sRAGE levels was correlated with whole blood cell count-derived inflammatory markers. A preliminary association between decreased sRAGE and overall survival in SCLC patients was observed.

Conclusions

Serum sRAGE shows potential as a blood-based biomarker reflecting metabolic, immune, and inflammatory status in lung cancer, warranting further investigation to clarify its prognostic and therapeutic relevance.

Schlagwörter

Stichwörter der Autor:innen

AGE-RAGE axisPD-L1 expressionbiomarkerslung canceroverall survivalsRAGEsoluble receptor for advanced glycation end products

Autor:innen und Institutionen

  • Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Endocrine Unit, Second Propaedeutic Department of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens,…

ORCID-Profile: Emmanouil Panagiotou, Eleftheria Karaviti, Dimitra Karaviti, Athanasios Kontogiannis, Elias Kotteas

Zitieren

APA

Panagiotou, E., Georganta, A., Garoflos, E., Karaviti, E., Karaviti, D., Kontogiannis, A., Chorianopoulou, S., Kotteas, E., Syrigos, N., & Peppa, M. (2026). Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients. Journal of Personalized Medicine, 16(3), 140. https://doi.org/10.3390/jpm16030140

Vancouver

Panagiotou E, Georganta A, Garoflos E, Karaviti E, Karaviti D, Kontogiannis A, et al. Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients. Journal of Personalized Medicine. 2026;16(3):140. doi:10.3390/jpm16030140

BibTeX
@article{Panagiotou2026,
  author = {Panagiotou, Emmanouil and Georganta, Anastasia and Garoflos, Efstathios and Karaviti, Eleftheria and Karaviti, Dimitra and Kontogiannis, Athanasios and Chorianopoulou, Sofia and Kotteas, Elias and Syrigos, Nikolaos and Peppa, Melpomeni},
  title = {Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients},
  journal = {Journal of Personalized Medicine},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {140},
  doi = {10.3390/jpm16030140}
}
Kostenlos starten →